Bioxcel Therapeutics Inc (BTAI)

$1.31 +0.05 (3.97%)
Market Cap 38.91M
Revenue (ttm) 640,000.00
Net Income (ttm) -69.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,921.88%
Debt to Equity Ratio -0.95
Volume 515,600
Avg Vol 760,902
Day's Range N/A - N/A
Shares Out 30.88M
Stochastic %K 75%
Beta 0.30
Analysts Strong Sell
Price Target $14.60

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 475-238-6837
Address:
555 Long Wharf Drive, 12th Floor, New Haven, United States
CoffeeRocks
CoffeeRocks Jun. 25 at 2:33 AM
$BTAI $RLAY $ABSI $CODX Bio stocks running 🏃‍♂️
0 ¡ Reply
CoffeeRocks
CoffeeRocks Jun. 25 at 1:44 AM
$CODX $AEMD $BTAI $SLS https://share.google/iINko0bnsVQxj6xLn
0 ¡ Reply
Tanny86
Tanny86 Jun. 24 at 9:43 PM
$BTAI I am banking. God bless you all!!
0 ¡ Reply
CoffeeRocks
CoffeeRocks Jun. 24 at 4:47 PM
$CODX $BTAI
0 ¡ Reply
CoffeeRocks
CoffeeRocks Jun. 24 at 3:43 PM
$BTAI 7 day run here $AIXI $INHD
1 ¡ Reply
Bilipli
Bilipli Jun. 24 at 3:34 PM
$BTAI yeah pump up and offering.. they only have like 6mil cash and each month burn 4 mil... no partnership yet...
1 ¡ Reply
CoffeeRocks
CoffeeRocks Jun. 24 at 3:31 PM
$BTAI important to note 1.37$ to 4.04$ fast
0 ¡ Reply
wndyctyboy1975
wndyctyboy1975 Jun. 24 at 3:09 PM
$BTAI only .70 more and you can get back to January's numbers
0 ¡ Reply
DariHendrix
DariHendrix Jun. 24 at 1:54 PM
$BTAI okayyyy ✅
0 ¡ Reply
BigDicBandit
BigDicBandit Jun. 24 at 10:43 AM
$BTAI when we hitting that $14.60 12 month average or the $38 high lfg already
0 ¡ Reply
Latest News on BTAI
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

May 28, 2026, 7:00 AM EDT - 27 days ago

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)

2026-05-15T12:03:32.000Z - 5 weeks ago

BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 5 weeks ago

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

BioXcel Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 5 weeks ago

BioXcel Therapeutics Quarterly report: Q1 2026

BioXcel Therapeutics Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 5 weeks ago

BioXcel Therapeutics Earnings release: Q1 2026

BioXcel Therapeutics Transcript: Investor update

Apr 23, 2026, 2:00 PM EDT - 2 months ago

BioXcel Therapeutics Transcript: Investor update

BioXcel Therapeutics Slides: Investor update

Apr 23, 2026, 2:00 PM EDT - 2 months ago

BioXcel Therapeutics Slides: Investor update

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMIŽ in the At-Home Setting

Apr 17, 2026, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMIŽ in the At-Home Setting

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Apr 9, 2026, 7:53 PM EDT - 2 months ago

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

BioXcel Therapeutics enrolls first patients in BXCL501 trial

2026-04-08T11:09:11.000Z - 2 months ago

BioXcel Therapeutics enrolls first patients in BXCL501 trial

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

Apr 8, 2026, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

BioXcel Therapeutics price target lowered to $5 from $6 at H.C. Wainwright

2026-04-02T10:12:16.000Z - 2 months ago

BioXcel Therapeutics price target lowered to $5 from $6 at H.C. Wainwright

BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA

2026-04-01T11:09:26.000Z - 3 months ago

BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMIÂŽ in the At-Home Setting

Apr 1, 2026, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMIÂŽ in the At-Home Setting

BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)

2026-03-27T11:20:13.000Z - 3 months ago

BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)

BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMIŽ Approval in Outpatient Setting

Mar 27, 2026, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMIŽ Approval in Outpatient Setting

BioXcel Therapeutics Annual report: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Annual report: Q4 2025

BioXcel Therapeutics Earnings release: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Earnings release: Q4 2025

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Mar 11, 2026, 4:20 PM EDT - 3 months ago

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

Mar 10, 2026, 2:36 PM EDT - 3 months ago

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

BioXcel price target lowered to $6 from $10 at H.C. Wainwright

2026-03-05T13:59:23.000Z - 3 months ago

BioXcel price target lowered to $6 from $10 at H.C. Wainwright

BioXcel Therapeutics announces results from Phase 2 trial of BXCL501

2026-03-05T12:48:55.000Z - 3 months ago

BioXcel Therapeutics announces results from Phase 2 trial of BXCL501

BioXcel Therapeutics announces results from Phase 2 trial of BXCL501

2026-03-05T12:26:21.000Z - 3 months ago

BioXcel Therapeutics announces results from Phase 2 trial of BXCL501

BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal

Mar 5, 2026, 7:00 AM EST - 3 months ago

BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal

BioXcel Therapeutics Transcript: Status update

Feb 27, 2026, 2:00 PM EST - 4 months ago

BioXcel Therapeutics Transcript: Status update

BioXcel Therapeutics to host KOL roundtable on Alzheimer’s dementia

2026-02-19T12:16:19.000Z - 4 months ago

BioXcel Therapeutics to host KOL roundtable on Alzheimer’s dementia

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia

Feb 19, 2026, 7:00 AM EST - 4 months ago

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia

BioXcel completes updated market opportunity assessment for Igalmi

2026-02-12T12:14:02.000Z - 4 months ago

BioXcel completes updated market opportunity assessment for Igalmi

BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi

2026-01-20T12:06:39.000Z - 5 months ago

BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMIÂŽ Label Expansion in the At-Home Setting

Jan 20, 2026, 7:00 AM EST - 5 months ago

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMIÂŽ Label Expansion in the At-Home Setting

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Jan 15, 2026, 12:44 PM EST - 5 months ago

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

BioXcel Therapeutics appoints Pavao as acting CCO

2026-01-12T12:21:09.000Z - 5 months ago

BioXcel Therapeutics appoints Pavao as acting CCO

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMIÂŽ in the At-Home Setting

Jan 12, 2026, 7:00 AM EST - 5 months ago

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMIÂŽ in the At-Home Setting

BioXcel Therapeutics planning to submit sNDA seeking FDA approval for IGALMI

2026-01-07T12:05:31.000Z - 6 months ago

BioXcel Therapeutics planning to submit sNDA seeking FDA approval for IGALMI

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMIÂŽ

Jan 7, 2026, 7:00 AM EST - 6 months ago

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMIÂŽ

BioXcel Therapeutics Transcript: AGM 2025

Dec 12, 2025, 9:00 AM EST - 6 months ago

BioXcel Therapeutics Transcript: AGM 2025

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Dec 3, 2025, 7:00 AM EST - 7 months ago

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

BioXcel Therapeutics’ Igalmi supplement for new indication approved by FDA

2025-11-21T15:25:20.000Z - 7 months ago

BioXcel Therapeutics’ Igalmi supplement for new indication approved by FDA

BioXcel Therapeutics reports Q3 EPS ($2.18), consensus ($1.34)

2025-11-12T12:16:09.000Z - 8 months ago

BioXcel Therapeutics reports Q3 EPS ($2.18), consensus ($1.34)

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease

Nov 12, 2025, 7:00 AM EST - 8 months ago

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease

BioXcel Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

BioXcel Therapeutics Quarterly report: Q3 2025

BioXcel Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

BioXcel Therapeutics Earnings release: Q3 2025

BioXcel Therapeutics Proxy statement: Proxy Filing

Nov 12, 2025, 7:00 AM EST - 8 months ago

BioXcel Therapeutics Proxy statement: Proxy Filing

BioXcel Therapeutics Proxy statement: Proxy Filing

Oct 31, 2025, 8:00 AM EDT - 8 months ago

BioXcel Therapeutics Proxy statement: Proxy Filing

BioXcel announces results from correlation study from SERENITY At-Home trial

2025-10-14T11:05:08.000Z - 9 months ago

BioXcel announces results from correlation study from SERENITY At-Home trial

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

Oct 14, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

Oct 13, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

BioXcel Therapeutics regains compliance with Nasdaq

2025-09-18T11:11:17.000Z - 9 months ago

BioXcel Therapeutics regains compliance with Nasdaq

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

Sep 18, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

BioXcel Therapeutics Transcript: Study Result

Sep 10, 2025, 2:00 PM EDT - 10 months ago

BioXcel Therapeutics Transcript: Study Result

BioXcel Therapeutics Press release: Study Result

Sep 10, 2025, 2:00 PM EDT - 10 months ago

BioXcel Therapeutics Press release: Study Result

BioXcel Therapeutics Slides: Study Result

Sep 10, 2025, 2:00 PM EDT - 10 months ago

BioXcel Therapeutics Slides: Study Result

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

Sep 10, 2025, 6:30 AM EDT - 10 months ago

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:30 PM EDT - 10 months ago

BioXcel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMIÂŽ

Aug 27, 2025, 8:00 AM EDT - 10 months ago

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMIÂŽ

BioXcel Therapeutics Transcript: Study Update

Aug 27, 2025, 8:00 AM EDT - 10 months ago

BioXcel Therapeutics Transcript: Study Update

BioXcel Therapeutics Press release: Study Update

Aug 27, 2025, 8:00 AM EDT - 10 months ago

BioXcel Therapeutics Press release: Study Update

BioXcel Therapeutics Slides: Study Update

Aug 27, 2025, 8:00 AM EDT - 10 months ago

BioXcel Therapeutics Slides: Study Update

BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:29 AM EDT - 10 months ago

BioXcel's agitation drug meets main goal in at-home study

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMIÂŽ

Aug 27, 2025, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMIÂŽ

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

Aug 26, 2025, 4:00 PM EDT - 10 months ago

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 19, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 18, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Transcript: H.C. Wainwright & Co. “HCW@Home” Series 2025

Aug 14, 2025, 1:00 PM EDT - 11 months ago

BioXcel Therapeutics Transcript: H.C. Wainwright & Co. “HCW@Home” Series 2025

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Aug 13, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

BioXcel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 12:00 PM EDT - 11 months ago

BioXcel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

Aug 12, 2025, 7:55 AM EDT - 11 months ago

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

BioXcel Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Quarterly report: Q2 2025

BioXcel Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Earnings release: Q2 2025

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Aug 11, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

Aug 6, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 1, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMIÂŽ

Jul 21, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMIÂŽ

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Jul 1, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 8:01 AM EDT - 1 year ago

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

May 27, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BioXcel Therapeutics Quarterly report: Q1 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Quarterly report: Q1 2025

BioXcel Therapeutics Earnings release: Q1 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Earnings release: Q1 2025

BioXcel Therapeutics Annual report: Q4 2024

Mar 27, 2025, 10:30 AM EDT - 1 year ago

BioXcel Therapeutics Annual report: Q4 2024

BioXcel Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 10:30 AM EDT - 1 year ago

BioXcel Therapeutics Earnings release: Q4 2024

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Mar 27, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 11, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 7, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

Mar 4, 2025, 4:15 PM EST - 1 year ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Mar 3, 2025, 3:33 PM EST - 1 year ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

Mar 3, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 28, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

BioXcel Therapeutics Announces Reverse Stock Split

Feb 6, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Reverse Stock Split

BioXcel Therapeutics Registration statement: Registration Filing

Jan 10, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Registration statement: Registration Filing

BioXcel Therapeutics Proxy statement: Proxy Filing

Dec 30, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Proxy statement: Proxy Filing

BioXcel Therapeutics Proxy statement: Proxy Filing

Dec 18, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Proxy statement: Proxy Filing

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Nov 22, 2024, 8:16 AM EST - 1 year ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

BioXcel Therapeutics Announces Proposed Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2024

BioXcel Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Quarterly report: Q3 2024

BioXcel Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Earnings release: Q3 2024

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference

CoffeeRocks
CoffeeRocks Jun. 25 at 2:33 AM
$BTAI $RLAY $ABSI $CODX Bio stocks running 🏃‍♂️
0 ¡ Reply
CoffeeRocks
CoffeeRocks Jun. 25 at 1:44 AM
$CODX $AEMD $BTAI $SLS https://share.google/iINko0bnsVQxj6xLn
0 ¡ Reply
Tanny86
Tanny86 Jun. 24 at 9:43 PM
$BTAI I am banking. God bless you all!!
0 ¡ Reply
CoffeeRocks
CoffeeRocks Jun. 24 at 4:47 PM
$CODX $BTAI
0 ¡ Reply
CoffeeRocks
CoffeeRocks Jun. 24 at 3:43 PM
$BTAI 7 day run here $AIXI $INHD
1 ¡ Reply
Bilipli
Bilipli Jun. 24 at 3:34 PM
$BTAI yeah pump up and offering.. they only have like 6mil cash and each month burn 4 mil... no partnership yet...
1 ¡ Reply
CoffeeRocks
CoffeeRocks Jun. 24 at 3:31 PM
$BTAI important to note 1.37$ to 4.04$ fast
0 ¡ Reply
wndyctyboy1975
wndyctyboy1975 Jun. 24 at 3:09 PM
$BTAI only .70 more and you can get back to January's numbers
0 ¡ Reply
DariHendrix
DariHendrix Jun. 24 at 1:54 PM
$BTAI okayyyy ✅
0 ¡ Reply
BigDicBandit
BigDicBandit Jun. 24 at 10:43 AM
$BTAI when we hitting that $14.60 12 month average or the $38 high lfg already
0 ¡ Reply
AllAboutTheBread
AllAboutTheBread Jun. 23 at 1:50 PM
$BTAI rooting for you guys.
0 ¡ Reply
ZXSpectrumNext
ZXSpectrumNext Jun. 23 at 1:25 PM
$BTAI 💸
0 ¡ Reply
Tomthefirst
Tomthefirst Jun. 23 at 7:58 AM
$BTAI 👍
0 ¡ Reply
Bilipli
Bilipli Jun. 22 at 9:22 PM
$BTAI they only have somewhere 2 month cash at most... sp will go up and a big offering will come..
0 ¡ Reply
PolyesterJacket
PolyesterJacket Jun. 22 at 8:11 PM
$BTAI if we can surpass the 100 day moving average of $1.33, it would be the first time since October 2025
1 ¡ Reply
PolyesterJacket
PolyesterJacket Jun. 22 at 8:10 PM
$BTAI Firmly broke through the 50 day moving average ($1.15). Next is 100 day average at $1.33 Followed by 150 day moving average of $1.51 200 day moving average of $1.77 would be very bullish sign
0 ¡ Reply
WenABVEAudit
WenABVEAudit Jun. 22 at 8:01 PM
$BTAI interesting close… WEN $8??
0 ¡ Reply
ENTERGALACTIC47
ENTERGALACTIC47 Jun. 22 at 7:59 PM
$BTAI
0 ¡ Reply
DariHendrix
DariHendrix Jun. 22 at 5:33 PM
$BTAI interesting movement here .. only green on my list 😅
1 ¡ Reply
Weenessie
Weenessie Jun. 22 at 3:26 PM
$BTAI nice.
1 ¡ Reply
ENTERGALACTIC47
ENTERGALACTIC47 Jun. 22 at 1:59 PM
$BTAI 🚀🚀🚀🚀
0 ¡ Reply
wndyctyboy1975
wndyctyboy1975 Jun. 22 at 1:58 PM
$BTAI can we hold gains today??
0 ¡ Reply